CDK4 and breast carcinoma: Palbociclib, ribociclib, and abemaciclib, three CDK4/6i, have been respectively validated for their efficacy and safety in treating breast cancer through landmark phase 3 clinical trials, namely PALOMA‐2,5 MONALEESA‐2,6 and MONARCH‐2.7